ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 333

Assessing the Relationship Between Gout and Return to Hemodialysis Among U.S. Renal Transplant Patients

Justin Li1, David Yin 1, Zheng Wang 1, Mark Brigham 1, Brian LaMoreaux 2, Jeffrey Kent 2, Megan Francis-Sedlak 2, Richard Johnson 3, Nandini Hadker 1 and Gavin Miyasato 1, 1Trinity Partners, Waltham, MA, 2Horizon Therapeutics plc, Lake Forest, IL, 3University of Colorado Denver, Aurora, CO

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: gout, hyperuricemia and renal disease, outcomes, transplantation

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Title: Metabolic & Crystal Arthropathies Poster I: Clinical

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Although gout has been shown to be associated with poor renal outcomes among chronic kidney disease populations, this relationship is not well understood among renal transplant recipients. This analysis compared rates of return to maintenance hemodialysis, a negative transplant outcome, across three primary renal transplant patient cohorts based on gout status: non-gout, pre-existing gout, and new-onset gout following transplantation.

Methods: This retrospective study of the United States Renal Data System examined Medicare beneficiaries who received a primary renal transplant between 2008-2013. Patients’ Medicare claims data were used to identify pre-existing gout in the 2 years prior to transplant and new-onset gout in the 3 years post-transplant. To mitigate the effect of complications associated with acute allograft rejection/ failure, recipients who died, returned to dialysis, or received re-transplantation within 3 years after primary renal transplantation were excluded. Patients’ return to hemodialysis was observed in the period between 3-5 years post-transplantation. The association between gout status (non-gout, pre-existing, and new-onset) and 5-year return to dialysis was evaluated via chi-squared tests.

Results: 39,780 patients received a primary renal transplant between 2008-2013 with Medicare as their primary payer after exclusions. Of these patients, 33,105 (83.2%) were non-gout, 4,747 (11.9%) had pre-existing gout, and 1,928 (4.8%) developed new onset gout post-transplant. 2,211 (5.6%) primary renal transplant recipients returned to hemodialysis between 3 and 5 years post-transplantation. The rate of return to hemodialysis 3 to 5 years after transplantation for non-gout, pre-existing gout, and new onset gout was 5.6, 4.6, and 7.5%, respectively (all pairwise comparisons yielded p< 0.05).

Conclusion: Compared to non-gout and pre-existing gout patients who received a primary renal transplant, patients who developed new-onset gout after transplantation were more likely to require maintenance hemodialysis, a negative renal transplant outcome. Further investigation is needed to determine if the presence and timing of gout relative to renal transplantation is an independent predictor for return to dialysis.


Disclosure: J. Li, Horizon Pharma, 2; D. Yin, Horizon Therapeutics plc, 2; Z. Wang, Horizon Therapeutics plc, 2; M. Brigham, Horizon Therapeutics plc, 2; B. LaMoreaux, Horizon, 3, 4; J. Kent, Horizon, 3, 4; M. Francis-Sedlak, Horizon, 3, 4, Horizon Therapeutics, 3, 4; R. Johnson, XORT Therapeutics, 1, 4, 5, Colorado Research Partners LLC, 1, 4, Danone Research Foundation, 2, 5, Horizon Therapeutics plc, 5; N. Hadker, Horizon Therapeutics plc, 2; G. Miyasato, Horizon Therapeutics plc, 2.

To cite this abstract in AMA style:

Li J, Yin D, Wang Z, Brigham M, LaMoreaux B, Kent J, Francis-Sedlak M, Johnson R, Hadker N, Miyasato G. Assessing the Relationship Between Gout and Return to Hemodialysis Among U.S. Renal Transplant Patients [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/assessing-the-relationship-between-gout-and-return-to-hemodialysis-among-u-s-renal-transplant-patients/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/assessing-the-relationship-between-gout-and-return-to-hemodialysis-among-u-s-renal-transplant-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology